Suppression of Prostate Cancer Metastasis by DPYSL3-Targeted saRNA

Area of Science:

• Oncology
• Molecular Biology
• Gene Therapy

Background:

• Metastasis is the primary cause of cancer mortality, with limited curative options.
• Cellular protein CRMP4, encoded by the DPYSL3 gene, acts as a metastasis suppressor in prostate cancer.
• Reduced CRMP4 expression correlates with lymphatic metastasis, while its overexpression inhibits cancer cell migration and invasion.

Purpose of the Study:

• To develop a CRMP4-based therapeutic strategy to combat prostate cancer metastasis.
• To utilize small activating RNA (saRNA) technology to enhance CRMP4 expression in prostate cancer cells.

Main Methods:

• Synthesis and screening of 14 saRNAs targeting the DPYSL3 gene in prostate cancer cell lines.
• Evaluation of saRNA efficacy on DPYSL3 gene expression at mRNA and protein levels.
• Assessment of saRNA effects on prostate cancer cell migration and invasion in vitro and in vivo.
• Utilizing PSMA aptamer-mediated cell homing for targeted delivery of saRNAs in an orthotopic mouse model.

Main Results:

• Two saRNAs targeting the DPYSL3 isoform-2 promoter significantly enhanced DPYSL3 gene expression.
• These saRNAs effectively suppressed prostate cancer cell migration and invasion both in vitro and in vivo.
• Targeted delivery of saRNAs via PSMA aptamers blocked distal metastasis in a preclinical mouse model.

Conclusions:

• saRNA-mediated enhancement of DPYSL3 (CRMP4) expression is a viable strategy for suppressing prostate cancer metastasis.
• This approach holds potential as a novel therapeutic avenue for cancer management.